retatrutide type 2 diabetes phase 2 trial

retatrutide type 2 diabetes phase 2 trial Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, conducted in the USA In the Phase 3 TRANSCEND-T2D-1

Name: retatrutide type 2 diabetes phase 2 trial Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, conducted in the USA In the Phase 3 TRANSCEND-T2D-1
Brand: quatrefleurs.de
SKU: 91667658718
Price: 26.04 USD
Availability: InStock
Rating: 4.7902000000000005 (21 reviews)

SKU: 91667658718

4.8

USD26.04 USD73.04

Pay in 4 interest-free payments of $6.51 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Jul 30 - Aug 4

Description

The North America obesity GLP-1 market size is estimated at USD 4.93 billion in 2025 and is projected to reach approximately USD 40.27 billion by 2035, with a 23.37% CAGR from 2026 to 2035

Full-dose GLP-1 therapy focuses on treating obesity and metabolic disease

Dairy products like yogurt, milk, and cheese are also "important for calcium and vitamin D, nutrients at particular risk of deficiency during GLP-1 therapy, given reduced overall food intake," she says